




Searching News Database: cyclophosphamide
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 27 Jul 2018
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
Accord Healthcare’s (Intas) Pelgraz(R) (pegfilgrastim) Given Green Light by CHMP
HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 11 Oct 2011
Aduro BioTech Announces First Patient Treated in Phase 2 Pancreatic Cancer Trial
Aduro BioTech Announces First Patient Treated in Phase 2 Pancreatic Cancer Trial
HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 8 Nov 2010
ZIOPHARM Oncology Appoints Brian L. Hamilton, M.D., Ph.D., as Senior Vice President, Clinical Operations
ZIOPHARM Oncology Appoints Brian L. Hamilton, M.D., Ph.D., as Senior Vice President, Clinical Operations
HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
HSMN NewsFeed - 6 Apr 2010
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
HSMN NewsFeed - 23 Mar 2010
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
HSMN NewsFeed - 8 Jul 2009
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals
HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
HSMN NewsFeed - 27 May 2008
Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
HSMN NewsFeed - 11 Feb 2008
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
HSMN NewsFeed - 17 Dec 2007
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
HSMN NewsFeed - 6 Jun 2007
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
HSMN NewsFeed - 10 May 2007
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
HSMN NewsFeed - 20 Mar 2007
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
HSMN NewsFeed - 8 Mar 2007
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
HSMN NewsFeed - 7 Feb 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
HSMN NewsFeed - 14 Dec 2006
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
HSMN NewsFeed - 29 Nov 2006
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
HSMN NewsFeed - 6 Nov 2006
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
HSMN NewsFeed - 31 Oct 2006
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
HSMN NewsFeed - 17 Oct 2006
Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma
Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma
HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
HSMN NewsFeed - 27 Sep 2006
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
HSMN NewsFeed - 15 Sep 2006
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
HSMN NewsFeed - 6 Sep 2006
Genzyme Begins Phase 3 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
Genzyme Begins Phase 3 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia
HSMN NewsFeed - 17 Jul 2006
Michael Tansey, M.D. Joins La Jolla Pharmaceutical Company as Chief Medical Officer
Michael Tansey, M.D. Joins La Jolla Pharmaceutical Company as Chief Medical Officer
Additional items found! 116

Members Archive contains
116 additional stories matching:
cyclophosphamide
(Password required)
cyclophosphamide
(Password required)